Our previous study reported that reasonable dose of antiangiogenic agents could induce the polarization of M2 tumor-associated macrophages to M1 tumor-associated macrophages in TIME of lung cancer, subsequently potentiating the antitumor effect of PD-1/PD-L1 inhibitors [29]. The gene discussed is PDCD1; the disease is lung cancer.